James Caress, MD, directs the ALS Center and has over 15 years of experience helping patients fight ALS. He has participated in over 20 clinical trials and other research projects designed to treat or understand ALS. ALS research at Wake Forest is divided into 2 equal parts that work together to test promising therapies and develop new ideas about the cause of ALS which generate novel treatments. The Translational Science Unit (TSU) aims to illuminate the cause and progression of ALS and to test novel therapies that can slow the progression of the disease. The TSU recently received a major grant to study the process of the nerves disconnecting from the muscles at the earliest stages of ALS. Learning about this process may lead to new ideas about how to keep these connections intact.
Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf. 2010; 9(6):971-979. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009; 256(3):339-342. Yoshikawa M, Vinsant S, Mansfield CM, Gifondorwa DJ, Pace L, Messi LM [sic] [Messi ML], Caress J, Cartwright M, Delbono O, Oppenheim RW, Milligan CE, et al. Identification of changes in muscle, neuromuscular junctions and spinal cord at early pre-symptomatic stages in the mutant SOD1 mouse model of ALS may provide novel insight for diagnosis and treatment development [abstract]. Soc Neurosci Abstr. 2009; 2009(Neuroscience Meeting Planner):. Cartwright MS, Brown ME, Eulitt P, Walker FO, Lawson VH, Caress JB. Diagnostic nerve ultrasound in Charcot-Marie-Tooth disease type 1B. Muscle Nerve. 2009; 40(1):98-102. Cartwright MS, Passmore LV, Yoon J-S, Brown ME, Caress JB, Walker FO. Cross-sectional area reference values for nerve ultrasonography. Muscle Nerve. 2008; 37(5):566-571. Caress JB. Technical, physiological and anatomic considerations in nerve conduction studies. In: Blum AS, Rutkove SB, eds. The clinical neurophysiology primer. Totowa (NJ): Humana Press; 2007: 217-227. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D, Al-Lozi M, Caress JB, David W, Russell J, Graves M, et al. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve. 2007; 35(2):228-234. Gifondorwa DJ, Robinson MB, Hayes CD, Taylor AR, Prevette DM, Oppenheim RW, Caress J, Milligan CE. Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2007; 27(48):13173-80. Caress JB, Esper GJ, Rutkove SB. Neurophysiology of nerve conduction studies. In: Blum AS, Rutkove SB, eds. The clinical neurophysiology primer. Totowa (NJ): Humana Press; 2007: 207-216. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Donofrio P, Caress J, Ashburn C, Walker T, Dryman B, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006; 60(1):22-31. Shoulson I, Kieburtz K, Oakes D, Kayson E, Zhao H, Shinaman A, Romer M, Caress J, Walker F, Hunt V, et al. At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) Cohort enrolled. Arch Neurol. 2006; 63(7):991-996.